<DOC>
	<DOCNO>NCT02206815</DOCNO>
	<brief_summary>The aim study assess safety antithrombotic drug ticagrelor plus oral anticoagulation adopt persistent permanent AF ( Atrial fibrillation ) patients（CHA2DS2VASc≥2） PCI-S specially regard occurrence major bleed complication . We hypothesize baseline characteristic ( ie age , anemia , previous major bleed ) type antithrombotic regimen could influence bleed event time bleed occurrence . We test hypothesis compare AF patient subsequently receive double antithrombotic therapy ( Ticagrelor + Warfarin ) vs. triple antithrombotic therapy ( Clopidogrel + Aspirin + Warfarin ) undergo PCI-S .</brief_summary>
	<brief_title>Safety `` Ticagrelor+ Warfarin '' Comparison With `` Clopidogrel+Aspirin+Warfarin ''</brief_title>
	<detailed_description>Currently , optimal antithrombotic treatment AF patient indication long-term oral anticoagulation undergo PCI-S unknown . The randomized trial assess best antithrombotic regimen set management population challenge . It pose imperative demand future prospective randomize study define optimal antithrombotic regimen patient require chronic anticoagulation undergo coronary stenting . Additionally , vast majority current clinical study antithrombotic therapy atrial fibrillation together PCI retrospectively analysis date , whereas prospective study rare urgently need</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Volunteered participate study sign informed consent form ; Men nonpregnant woman ≥ 18 ≤75 year age ; Lesion locate coronary artery need coronary drugeluting stent implantation ; Patients persistent permanent atrial fibrillation ; Score CHA2DS2VASc≥2 . Severe liver kidney disease ( GFR &lt; 60 ml/min/1.73m2 CTP≥6 score ) ; Moderate severe hypertension ( standard antihypertensive therapy , blood pressure high 160/100mmHg ) ; Patients hemodynamic electrical instability ( include shock ) ; Coagulation disorder associate significant bleeding tendency ( eg , hypersensitivity , active bleeding , moderate severe liver disease , history previous intracranial bleed , GI bleed within past 6 month , major surgery within 30 day ) ; Patients ischemic stroke within one week ; Patients Bronchial asthma , Chronic obstructive pulmonary disease ( COPD ) , patient disease related dyspnoea ; Any contraindication use ticagrelor study drug ; Platelet count le 100 x 109/L ; Haemoglobin ( Hb ) level le 100 g/L ; Researchers involve study / immediate family member ; Participation another investigation drug device study past 30 day enrollment ; Involvement plan conduct study ( applies staff study site ) ; Suffering serious disorder life expectancy less half year ; Increased risk bradycardic event ( e.g . pacemaker know sick sinus syndrome , second degree AV block , third degree AV block previous document syncope suspect due bradycardia ) . The Sponsor review Holter data study ass need continue exclusion ; Pregnancy lactation female childbearing potential plan pregnancy one year ; Concomitant oral intravenous therapy ( see example ) strong CYP3A inhibitor , CYP3A substrates narrow therapeutic index , strong CYP3A inducer stop course study （Strong inhibitor : ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazadone , ritonavir , saquinavir , nelfinavir , indinavir , atanazavir ; Substrates narrow therapeutic index : cyclosporine , quinidine；Strong inducer : rifampin/rifampicin , phenytoin , carbamazepine ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>